PARABDRUGS

The Exchange had sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company was required to clarify the following: -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format. -3. Financial results not submitted as per Schedule III to the Companies Act, 2013The response of the Company is enclosed.

Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 21, 2017.1.Recommended the appointment of M/s. V.K. Jindal & Associates, Chartered Accountants as Statutory Auditors of the Company for a period of one year and the same would be presented for the approval of Shareholders at the forthcoming AGM. There office is located at S.C.O. 41, Second Level, Madhya Marg, Sector 20, Chandigarh. M/s. V.K. Jindal & Associates has vast experience in handling accounts auditing and other related matters.2.Re-appointed Mr. Harbans Lal as Internal Auditor of the Co

The Exchange has sought clarification from Parabolic Drugs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.On basis of above the Company is required to clarify. -1. Reconciliation of profit and loss not submitted. -2. Financial results not submitted as per Ind-AS format. -3. Financial results not submitted as per Schedule III to the Companies Act, 2013The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.

Parabolic Drugs Limited has informed the Exchange regarding Auditors report for the period ended March 31, 2017.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2017, regarding Outcome of Board Meeting held on May 29, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 29-May-2017, regarding Outcome of Board Meeting held on May 29, 2017. On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on May 29, 2017.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.

PARABDRUGS:The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 10-May-2017, regarding "Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is attached..

Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017. Mr. Ashok Kumar Jindal has a rich experience of around forty years. Mr. Jindal has handled various accounting matters. He has also handled responsibilities with respect to sales tax, Insurance, Banking etc. He has a dynamic experience of handling various matters concerning the above mentioned spheres from which the organization will benefit vastly. You are requested to take the above said information on your record a

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 10-May-2017, regarding "Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.

Parabolic Drugs Limited has informed the Exchange regarding Appointment of Mr Ashok Kumar Jindal as Chief Financial Officer of the company w.e.f. May 10, 2017.

SBICAP Trustee Company Ltd. has submitted to the Exchange the disclosure under regulation 30(1) and 30(2) of SEBI (SAST) Regulations, 2011.

Parabolic Drugs Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on February 09, 2017 : (1) To take note that ICICI Bank, IDBI Bank, State Bank Of India, State Bank of Hyderabad, State Bank of Patiala and UCO Bank has assigned their debt in favor of JM Financial Asset Reconstruction Company Private Limited.

PARABDRUGS: The Exchange had sought clarification from Parabolic Drugs Limited with respect to announcement dated 12-Nov-2016, regarding "Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 12, 2016: Inter alia.1) To take note of the resignation of Chief Financial Officer, Mr. Sandeep Sharma of the company.".On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is enclosed.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to announcement dated 12-Nov-2016, regarding "Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 12, 2016: Inter alia.1) To take note of the resignation of Chief Financial Officer, Mr. Sandeep Sharma of the company.".On basis of above the Company is required to clarify following:1. Date of appointment/cessation (as applicable) & term of appointment;The response of the Company is awaited.

Parabolic Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2016.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on November 12, 2016: Inter alia.1) To take note of the resignation of Chief Financial Officer, Mr. Sandeep Sharma of the company.

Parabolic Drugs Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on September 29, 2016.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Parabolic Drugs Limited has submitted their response.

Significant increase in price has been observed in Parabolic Drugs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.

Parabolic Drugs Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the September 29, 2016.

Parabolic Drugs Limited has submitted to the Exchange a copy of the Combined Scrutinizer s Report on the E-voting and Poll conducted in respect of the resolution set out in the Notice convening Annual General Meeting of the Company.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Members of the Company held on September 29, 2016.

Parabolic Drugs Limited has submitted to the Exchange a copy of newspaper published notice of Annual general Meeting of the Company to be held on September 29, 2016

Parabolic Drugs Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from September 23, 2016 to September 29, 2016(both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on September 29, 2016

The Exchange had sought clariification from Parabolic Drugs Limited with respect to an announcement submitted to the Exchange dated August 13, 2016, regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016 wherein board has appointed Mr. Sandeep Sharma, as Chief Financial Officer of the Company.On basis of above, The Company has clarified that :"1. Mr. Sandeep Sharma was appointed as Chief Financial officer of the Company w.e.f. 13-08-2016. 2. There is no relationship between Mr. Sandeep Sharma and any of the Director of the Company. 3. Brief profile of Mr.

PARABDRUGS:The Exchange has sought clarification from Parabolic Drugs Limited with respect to an announcement submitted to the Exchange dated August 13, 2016, regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016 wherein board has appointed Mr. Sandeep Sharma, as Chief Financial Officer of the Company.On basis of above Company are required to clarify following -1. Date of appointment/cessation (as applicable) & term of appointment;2. Disclosure of relationships between directors (in case of appointment of a director).3. Brief profile (in case of appointm

Parabolic Drugs Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on August 13, 2016.

Parabolic Drugs Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

Parabolic Drugs Limited has informed the Exchange regarding Decleration on Audit Qualification.

Parabolic Drugs Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on May 28, 2016: 1. Appointed R.K. Bhalla & Associates, Practicing Company Secretary as Secretarial Auditor of the Company

SBICAP Trustee Company Ltd. has submitted to the Exchange vide letter dated April 06,2016 a copy of disclosure under Regulation 30(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 13, 2016: (1) Resignation of Ms Mallika Seth from the post of Company Secretary of the Company.

Parabolic Drugs Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended December 31, 2015.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on December 17, 2015: (1). Appointed Ms. Mallika Seth, as a Company Secretary of the Company.(2). Appointed Mr. Sanjeev Kumar, as an Independent Director on the Board of Directors of the Company.

Parabolic Drugs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2015.

Parabolic Drugs Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on September 29, 2015.

Parabolic Drugs Limited has submitted to the Exchange a copy of the Scrutinizer's Report of the Annual General Meeting of the Company held on September 29, 2015.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of the Annual General Meeting of the Members of the Company held on September 29, 2015.

Parabolic Drugs Limited has informed the Exchange regarding the Outcome of Annual General Meeting of the Company held on September 29, 2015.

Parabolic Drugs Limited has informed the Exchange that the Company has fixed Book Closure from September 23, 2015 to September 29, 2015 for the purpose of Annual Closing

Parabolic Drugs Limited has informed the Exchange that the voting rights of shareholders in respect of the items set out in the Notice of 19th Annual General Meeting shall be in proportion to their shareholding in the paid up equity share capital of the Company as on the cut-off date which has been fixed as September 22, 2015.

Parabolic Drugs Limited has submitted to the Exchange a copy of notice of Annual General Meeting of the members of the company to be held on September 29, 2015.

Parabolic Drugs Limited has informed the Exchange vide letter dated August 27, 2015 Addendum to the Outcome of Board Meeting held on August 14, 2015.

Parabolic Drugs Limited has informed the Exchange that the Board of Directors in its Meeting held on August 14, 2015:1. Approved the Performa & Annexure to be submitted with Cost Auditor report for the Financial Year 2014-15.2. Appointed DAV & Associates LLP, Chartered Accountants, as statutory auditors of the Company.